ALPS Group Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Form 20-F Annual Report Filing | 31 Oct 2026 |
| Nasdaq Minimum Bid Price Compliance Deadline | 11 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Whole Genome Sequencing (WGS) Clinical Adoption QuarterlyTarget: Expansion of clinical diagnostic services across Southeast Asian hospitals and research institutions following MS ISO 15189:2022 accreditation
Total Revenue Annually3.7MTarget: Sustain and grow commercial aesthetic, general healthcare, and wellness revenues to fund clinical pipeline development
Operating Cash Flow Quarterly-1.7MTarget: Improve cash conversion and manage operational expenses to reduce cash burn
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 per share for 30 consecutive business daysAction: Regain compliance by maintaining a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the November 11, 2026 deadline
- R&D Pipeline Funding and Cash RunwayTrigger: Cash and cash equivalents falling below critical operational thresholds (currently at $643,252 against $779,231 in total debt)Action: Optimize commercial revenue generation from aesthetic and wellness services to support pre-clinical R&D and clinical trial progression
Research as of 20 Jun 2026